Future developments in the selectivity of anticancer agents: Drug delivery and molecular target strategies

Cancer and Metastasis Reviews

Volumn 17, Issue 2, 1998, Pages 211-218

  Mayer, Lawrence D ^a,b  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Antisense; Chemotherapy; Drug delivery; Drug resistance; Gene therapy; Liposomes

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; DOXORUBICIN; GLYCOPROTEIN P; LIPOSOME; PROTEIN BCL 2; PROTEIN FARNESYLTRANSFERASE INHIBITOR; VALSPODAR; VINCRISTINE;

CANCER GROWTH; CANCER INHIBITION; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SELECTIVITY; DRUG TARGETING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTO ONCOGENE; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; GENE THERAPY; HUMANS; LIPOSOMES; NEOPLASMS; NEOPLASMS, EXPERIMENTAL;

EID: 0031816635     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006070906949     Document Type: Review

References (32)

1. Lasic DD, Papahadjopoulos D: Science 267: 1275-1276, 1995
2. Mastrangelo MJ, Berd D, Mathan FE, Lattime EC: Sem Oncol 23: 4-21, 1996
3. Mayer LD, Tai LCL, Ko DSC, Masin D, Ginsberg RS, Cullis PR, Bally MB: Cancer Res 49: 5922-5930, 1989
4. Gabizon A, Dagan A, Goren D, Barenholz Y, Fuks Z: Cancer Res 42: 4734-4739, 1982
5. Huang SK, Mayhew E, Gilani S, Lasic DD, Martin FJ, Papahadjopoulos D: Cancer Res 52: 6774-6781, 1992
6. Mayer LD, Dougherty G, Harasym TO, Bally MB: J Pharmacol Exp Therapeut 280: 1406-1414, 1997
7. Yuan F, Leunig M, Huang SK, Berk DA, Papahadjopoulos D, Jain RK: Cancer Res 54: 3352-3356, 1994
8. Webb MS, Harasym TO, Masin D, Bally MB, Mayer LD: Br J Cancer 72: 896-904, 1995
9. Subramanian D, Muller MT: Oncol Res 7: 461-469, 1995
10. Huang SK, Stauffer PR, Hong K, Guo JW, Phillips TL, Huang A, Papahadjopoulos D: Cancer Res 54: 2186-2191, 1994
11. Holland JW, Hui C, Cullis PR, Madden TD: Biochemistry 35: 2618-2624, 1996
12. Kirpotin D, Hong K, Mullah N, Papahadjopoulos D, Zalipsky S: FEBS Lett 388: 115-118, 1996
13. Ahmad I, Longenecker M, Samuel J, Allen TM: Cancer Res 53: 1484-1488, 1993
14. Marjan J, Charrios G, Lopes de Menezes D, Allen TM: Proc Amer Assoc Cancer Res 37: A2103, 1996
15. Lee RJ, Low PS: J Biol Chem 269: 3198-3204, 1994
16. Park JW, Hong K, Kirpotin DB, Papahadjopoulos D, Benz CC: Adv Pharmacol 40: 400-435, 1997
17. Mizuguchi H, Nakanishi M, Nakanishi T, Nakagawa T, Nakagawa S, Mayumi T: Br J Cancer 73: 472-476, 1996
18. Suzuki S, Inoue K, Hongoh A, Hashimoto Y, Yamazoe Y: Br J Cancer 76: 83-89, 1997
19. Gibbs JB, Oliff A: Ann Rev Pharmacol Toxicol 37: 143-166, 1997
20. Prins J, de Vries EGE, Mulder NH: Clin Oncol 5: 245-252, 1994
21. Hynos NE, Stern DF: Biochim Biophys Acta 1198: 165-184, 1994
22. Kartner N, Riorden JR, Ling V: Science 221: 1285-1288, 1983
23. Hickman JA: Eur J Cancer 32A: 921-926, 1996
24. Fan D, Beltran PJ, O'Brian CA: In: Kellen JA (ed) Reversal of Multidrug Resistance in Cancer. CRC Press, Boca Raton pp. 93-125, 1994
25. Gonzalez O, Colombo T, De Fusco M, Imperatori L, Zucchetti M, D'Incalci M: Cancer Chemother Pharmacol 36: 335-340, 1995
26. Weeb A, Cunningham D, Cotter F, Clarke PA, di Stefano F, Ross P, Corbo M, Dziewanowska Z: Lancet 349: 1137-1141, 1997
27. Cotter F, Hohnson P, Hall P, Pocock C, Al Mahdi N, Cowell J, Morgan G: Oncogene 9: 3049-3055, 1994
28. Felgner PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz M, Northrop JP, Ringold GM, Danielson M: Proc Natl Acad Sci USA 84: 7413-7417, 1987
29. Hofland H, Huang L: Biochem Biophys Res Commun 207: 492-496, 1995
30. Li S, Huang L: Gene Therapy 4: 891-900, 1997
31. Hong K, Zheng W, Baker A, Papahadjopoulos D: FEBS Lett 400: 233-237, 1997
32. Krishna R, Mayer LD: Cancer Res 57: 5246-5253, 1997